Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As we cited in a German study, Vascepa delayed dementia and Alzhheimer's in those not having a particular gene
As 'cheap' as Vascepa is you can expect the FDA will be all over it as will everyone. Amarin sits on more patents.
I continue to believe this is going to ignite a massive run in the pps (IMO). It will make Reduce It look small.
Eicosapentaenoic Acid Is Associated with Decreased Incidence of Alzheimer’s Dementia in the Oldest Old
"In conclusion, higher concentrations of EPA were associated with a lower incidence of AD dementia. In addition, we observed that higher concentrations of EPA were associated with a decreased risk for all-cause and AD dementia among APOE e4 non-carriers but not among APOE e4 carriers."
Drive $100M revenue above costs adding to bottom line Amarin is gold.
Breaking News: On Vascepa, Alzheimer's patients showed slowed progression.
That's what we all want to read. Well, let's DO IT!!!!!
(FOR ONCE) let's join hands on Alzheimer's!!!
We can argue all our differences later. Let's all mind-heart-soul, focus on Vascepa vs Alzheimer's!
We'll be rich beyond measure!!!!
Now... focus....
Holt acknowledged the share price is under book valuation. Holt also made clear the statin-combo in not a priority. Holt also made clear thru savvy maneuvering, the company is gaining cash on hand. Holt didn't avoid the USA or UK challenges. But what Holt didn't say was how Vascepa may radically address Alzheimer's, nor should he. I suspect Holt like us is waiting to hear the results. For once, can we all come together, forget our differences, and hope beyond hope Vascepa should be prescribed to Alzheimer's patients. I'm done. Thank you.
Put ‘short’ next to any poster mentioning reverse split, delisting or bankruptcy. They are liars.
My face is under keg tap at this point, I’m glad I’m invested for 19 yr horizon. Saw Holt entering a pub not looking to cheery
Remove 5% of float makes a lot of good sense costing 20M because I’m sleeping in the pub
Remove 5% of float makes a lot of good sense costing 20M because I’m sleeping in the pub
Pub time?
Reading on Austrailia IP, most recent 2023226708 Methods of reducing the risk of cardiovascular events in a subject
Direction to request examination
for patent application
Spruson & Ferguson
GPO Box 3898
Sydney NSW 2001
Australia
Your reference P0028238AUD5
Application number 2023226708
Applicant name Amarin Pharmaceuticals Ireland Limited
Request examination by: 12 November 2023.
Dear Spruson & Ferguson,
Under the provisions of section 44(2) of the Patents Act 1990 I direct the above named applicant to request
examination of this patent application.
I have issued this direction because either progress has been made in the examination of applications
filed before the filing date of this application or it is in the public interest. Please note that examination
must be requested on or before 12 November 2023 or this application will lapse.
A request for examination must include the required statement of the applicant(s) entitlement to the
grant of the patent and to claim priority from any application(s) listed in the patent request, or in an
applicable declaration under Article 8 of the PCT. If a request is incomplete it will be deemed not filed. In
that case, the application will lapse unless a new examination request is filed on or before 12 November
2023.
You can file an examination request using online services.
Details of this patent application can be viewed on AusPat, our Australian patent search database.
Yours sincerely,
Commissioner of Patent
Part 4: Do you know what? There are many KISS-UPS on the Amarin board. La! La, La! always drinking milk the boys in whiling about how they horrible bringing up yet every one has a tubby belly and never laughs over a pint...
I know the N-3. Do you? Ha! Yer a lot of pony boys!!! Go home to yer momma's wee milking lads. Go back to the Blue Mary in Trim/ Tell Mary how yer sorry
Part 3 - What we offer is what others won't offer - Amarin is up for sale?
There's not going to be a give-away, no low-ball offer, no panic. Amarin can just keep building global buyers.
You who are focused on the USA, you would be helped by those of us who actually KNOW IRELAND. Wanna drink with me on the road to Trim? How about where the bus stops off? What if we forget and end up beyond Trim? Q: Do you walk off the bus???
Part 2 - Amarin will kick the "Irish advantage" down the road the very day BP offers a much bigger pay day You need to realize: Holt/Denner have advertised Amarion is 'up for sale'
Part 1: Amarin is ONLY IN IRELAND FOR TAX REASONS. THAT'S THE HONEST TRUTH.
People investing in Amarin need to know the REAL STORY.
Indeed, the 'Hill of Slane' on N2.... oh and 'Dunshaughlin' spelling correct...
Can you imagine as we did our children climbing the spoils of Slane (close to imfamous Slane castle now hawking whiskey) climbing...
Death feet above then telling mom and dad how high they were? THAT WAS IRELAND.
Sheep-crap our kids got in the car (reeking) and we drove home in County Meath (so-called 'King's County)
Back in those days ( 2,000= 2,020) Trim was a nothing but a movie. If you want to know the truth about Amarin, then just ask, because we live there, we lived there, we went to Liffey Valley Mall as Irish people did...
God bless all.
I prefer north side of the river but no higher. If south, I'll accept. I know Dublin streets very well. I do like the area around Trinity as anyone would. Being from Meath, anyone drinking to "Amarin's" success is welcome in my home. Should Amarin re-hit $26 I'd probably buy out 10 special stays in Trim, Co. Meath--that drinking Captain Beer would be first and I'd host him, what a guy! DO I KNOW COUNTY MEATH? Yes, I do as a decade of my life testifies: Dunshaughlin, Navan, and then Trim. I know a lot. Many memories. I know every drink point in Trim, Navan, and Dunshauglin. I know of places few will ever be privileged to visit.
The fact is: Amarin, correctly understood, could rise to $30 share in an instant. There is a lot of political stuff going on here... you'd be advise to consult 'links' this page will never cover... Ireland wants to crush Europe: Wake up! The Tiger is eager to come back!!!
It may be a stretch, but can we celebrate long-holder relationships on IHUB?
I know I'm among the newer gang, but I've held Amarin pre-Du so maybe that counts for something?
Captain, so many others, make my days better knowing as the share count reveals, a private shareholder base larger than what most biotechs ever have... and that's why there is a tiny float.... so manipulated. I sincerely hope Alex uses his contacts to squeeze that silly float in a positive direction--oh, I know he will!
So let's celebrate comradery, friendship, and positive thinking.
Deeply troubled I am, that I was accused of pumping.
Listen, I like many longs think the EPA potential is yet to be tapped. Holt's clearly laying the groundwork to build saleable value and was clear he's open to what is in the best interest of investors, including himself. On financials, cash alone, any inventory, sales, assets, Amarin's already below book value. When I envision where Alex and Brother Holt want to take Amarin, I'm in their corner and not afraid to assert my thinking in public. If Alzheimer's becomes a real possibility, then I say it's off to the races, and BP will be at Holt's door.
I think I have every right to feel excited about my long-term play. Being in penny land is just another opportunity to load up. The past is the past. I voted for the new BOD, I'm behind Alex, and I really prefer Holt over past CEOs--he seems to 'get it'. I also understand 'pumping' and 'dumping' but that's never my game. I still maintain hopes of double digits and I can sit another 7 years if necessary assuming Amarin builds out its portfolio. Sure, biotech is always a gamble, but many people are sailing in yachts because they assumed the risk, and won. I say Amarin's EPA is worth it, so if you don't like my posts, then just put me on ignore.
Only Germany and Italy are delayed. Only two countries where Amarin gains approval everywhere else. It's ever so obvious. Move to Central and South America and Africa, Amarin would rack up approvals. The success of this company is not hinged on Germany and/or Italy. BP could gain these anyway (and France if necessary). Perspective here.
THE USA MARKET REMAINS 'UNNNNNNNNNN-TAPPPPPED' - that is a fact based on current need vs current prescribers. It's all a game and BP knows how to play it.
The table is set for a BP to take Amarin's EPA and run as fast as they can. Let Alzheimer's kick in and BP will be making $$$ bids. Bank on it.
STRONG BUY: Amarin's cash, inventory, etc. is well below book value. Except for Italy and Germany, the company has met with approval success in the ROW. The USA market remains strong in the face of generics. Hidden from public view, Amarin already has a next-generation EPA, and optimism about Alzheimer's is very strong. The manipulated float is quite low. The oddity is Amarin has a very long private investor base holding the majority of shares. Institutions and insiders make up most of the rest other than the manipulated float. It is this long private investor percentage which makes this stock most unusual; the same 'unusual' that ousted a BOD and CEO. Should Sarissa add further shares or solicit a few HF croonies, the share price will rise, again and again. Private longs refuse to sell; bank on it.
Amarin is now Sarissa HF run with a selected CEO holding shares and a goal to take the company well-above $15/share for him to attain riches. Sarissa's Denner controls the BOD and CEO. I and other long investors have been adding shares in the downward trend which is entirely a very low float of shares. Long private investors are a powerful presence here and smart HFs along with Sarissa know what this means.
HF and private long investor, Amarin is sitting on a multi-billion dollar drug-opportunity, and everyone knows it. With the UK, Middle East, Asia (China), Australia-New Zealand jumping in along with the USA, the outlook looks like Amarin and its EPA franchise will garnish a hefty return in 2024. Any BP could accelerate EPA with their own drug portfolio (including the USA), but Amarin private longs will not go along easy--they already saw $26/share--they know about other diseases.
Getting in at $0.86 is one of those biotech-opportunities returning thousand percent gains. BTW, if Amarin's drug looks promising to Alzheimer's, YOU JUST MISSED THE BIG PAY-DAY. CVD should be enough, but research suggests EPA will ultimately be prescribed for more than one medical indication.
Clouded over in market conditions, AMRN shares offer a once in the lifetime dream.
Living the dream! Vascepa every day! Share count building. $0.86 x 10 = just the beginning. Believe in what you invest in! I do! I know first hand Vascepa is very safe and very efficacious scrubbing and cleaning, oh yeah! Let's give it up for Holt! He's the man!
Feeling SUPER tonight!
When you're buying a $100 pps company for 0.84c, you're HAPPY.
You remain one of my biggest heroes. I'm sorry you had to suffer.
Why did our hero CaptainBeer take a generic? Only he can answer.
i'm like one of your biggest fans, but i was REALLY confused to read you took a generic. You need to flesh this out for fellow fans. No offense, but I almost feel betrayed by the unthinkable
Great time to lower cost basis! In one account down to $3.42 cost basis which ain't bad! Meanwhile the long term payday is really looking sweet! The more long investors add, it slowly squeezes that manipulated float. I'm convinced Denner is working hard to increase new longs into the game to drive the price up again. Right now anyone can easily double their money or I believe 1000% plus when the Alzheimer's news hits the wires.
Honest? I am honest about what I post. I think Vascepa will have such a positive effect on the ONSET of dementia and Alzheimer, it will be a settled issue.
I then see the sp rocketing. WHY? Because Sarissa and every blooming HF will be buying!!!!
5000% gain here coming. Vascepa STAVES OFF onset of Alzheimer's. I think this will be THE NEWS STORY OF 2023-24.
Previous studies including Budoff especially support this conclusion.
Sarissa has the fire-power plus friends who will move the stock when it's time. Savvy investors will continue to add. This is a gift to achieve 100%- 1000% and higher gains. We're constantly adding. It only makes sense. Meanwhile if Alzheimer's news hits, here comes $87 pps in a rapid hurry and a lot of very wealthy long investors. I remain excited.
I came away with the opinion, the business at Amarin is now (versus previously) healthy, even robust after all the belt tightening. Holt, a fellow shareholder, offered his own angst with the share price, but pointed to how the build-out will bring about positive change in valuation. Twice, Holt mentioned he's only been with company "ten weeks" and even confessed to coming down with Covid, but he has already done what needed to be done before the next crisis which is get Amarin lean, mean, and in time a real revenue growth machine. Could be wrong, but looks like Italy employees except for maybe essential ones may be gone as they revisit the whole process. Let face it: A lot now is riding on success in France, and Holt seems aware of this. For the first time, I felt like Holt represented my interests as I continue to add shares.
Here's something you guys don't know
[url][/url][tag]https://www.law360.com/employment-authority/articles/1522655/former-amarin-exec-s-noncompete-brawl-likely-not-over-yet[/tag]
Out with the old...
Donna Pasek
Former Sr. VP, Human Resources at Amarin Corporation
Do any of these in Italy have jobs? Go here
I mean Germany got shut down. Why not Italy?
Four capsules of Vascepa and two Vitamin E, swallowed at once. Years ago I swallowed something like 15 vitamins in one blow. I'm hoping Amarin announces its making Vascepa in one mighty big bomb!
Thank you for allowing me to add insightful content to IHUB. Rough two days for me.
Anyone buying will see well beyond 400% gain by the time the Holt Denner BOD team is done and why I’ve been adding shares.
If we score on Alzheimer’s the share price is off to the races!!!!
Vascepa's ANTI/REVERSING Arteriosclerosis continues to be missed. Dr. Budoff offered in his study the proof of concept. This is so much more than triglycerides. Vascepa actually over time cleanses the blood. It baffles me why Amarin doesn't jump all over this data. And it's why I take Vascepa 2 years ongoing and will do so thereafter.
Why Denner appears quiet... it's because Holt is Denner, and Denner is Holt. They've since discovered the deep EPA enterprise AND realize this is a 5 even 10 year play. As Denner no doubt thinks, "I acquired at $5, so I'm okay with $50."
Trust this, if you want the vitality of a 20 yr old you'll consider how Vascepa keeps the ole' blood flow going.
What the Italy debacle illustrates is ignorance on someone's part, the lack of knowledge. Not only is CVD a major and severe medical condition, they don't grasp Vazkepa's anti-arteriosclerosis benefit above and beyond lowering triglycerides. Their class C designation is reminiscent of Judge Du guided by ulterior motives in this case extending life by years and not realizing the medical cost savings long-term. Somewhere in this application process, the economics of the science was never grasped by Italy's bean counters which means KM/Laurent either failed to properly communicate, stay on top of the communication stream, or the decision-makers in Italy are... well, let's just say... can go back to making pasta.
In Italy Amarin applied for class "A" (severe and chronic diseases) yet Italy gave it class "C" (Class C: other drugs whose cost is borne in full by the patient; this class includes OTCs (class c-bis) and SOPs and products that may already be sold on the market whose reimbursement by the SSN is yet to be negotiated (C-nn). Furthermore, some prescription drugs are also listed in class C (prescription is necessary to buy the drug, but the price is paid by the patient). OTCs and SOPs are not reimbursed.) https://www.globallegalinsights.com/practice-areas/pricing-and-reimbursement-laws-and-regulations/italy
The translate text reads: Having regard to the opinions rendered by the Price and Reimbursement Committee at its meetings on
June 19-21 and 27, 2023, and in the sitting of July 18-20, 2023;
Having regard to the official records;
Determines:
Article 1
Classification for the purpose of reimbursability
The medicinal product VAZKEPA (icosapent ethyl) in the packages below
indicated is classified as follows.
Packaging:
"998 mg - soft capsule - oral use - bottle (HDPE)" 120
capsules - A.I.C. No. 049428016/C (base 10);
reimbursable class: "C";
"998 mg - soft capsule - oral use - blister (PVC/PCTFE/AL)" 4 ×
2 capsules (unit dose) - A.I.C. No. 049428028/C (base 10);
reimbursable class: "C".
Mr. Stockboy interpretation: By classifying Vazkepa as class C, Italy denied it would reimburse. Instead, it is treated like an OTC generic, so if Amarin wants to sell it in Italy, they can set a price like any generic. In fact, Italy denied Vazkepa qualified for chronic and severe illnesses which is like saying they didn't take the CVD data of the clinical study as life-saving, but more like "Hey... sure... take a-fish-oil capsule... but you pay for it!"
Diamond in the rough, comes to mind today.
More shares to add. It's all good.